Current treatment options for acanthosis nigricans

Nupur Patel1
Catherine Roach1
Hossein Alinia1
William W Huang1
Steven R Feldman1–3

1Department of Dermatology, Center for Dermatology Research, Wake Forest University School of Medicine, Winston-Salem, NC, 2Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC, 3Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA

Abstract: Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. While the goal of therapy is to treat the primary cause, cosmetic resolution of AN lesions can be important for patients and their quality of life. Treatment options for AN have not been extensively studied; however, smaller powered clinical trials and case reports exist in the literature. Our review aims to explore and evaluate the current treatment options that exist for AN.

Keywords: acanthosis nigricans, diabetes, obesity, hyperinsulinemia, dermatologic condition, dermatology, malignant acanthosis, pseudoacanthosis, metformin, isotretinoin, tretinoin, topical therapy

Background

Acanthosis nigricans (AN) is a common cutaneous condition that can be a manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. It is characterized by thick velvety hyperpigmented plaques of the intertriginous, flexural, and less commonly extensor areas of the skin.1 When AN is associated with internal malignancy, skin changes develop rapidly and are often accompanied by mucosal involvement, seborrheic keratoses, acrochordons, and tripe palms. In contrast, endocrinopathy-associated AN develops more insidiously and covers a smaller area of the body. Patients are often obese and may have a history or family history of diabetes or polycystic ovarian syndrome. Prevalence of AN among primary care patients in the USA has been reported to be as high as 19.4%.2 High-risk populations are African-Americans, Hispanics, and Native Americans, although this condition presents in all races.

The severity of AN has a positive correlation with fasting insulin levels.3 AN is likely the result of high levels of insulin binding to insulin-like growth factor 1 receptors (IGF-1Rs) on keratinocytes and fibroblasts. This leads to a proliferation of both cell types and clinically apparent plaques and papillomatosis.3 In addition, high levels of insulin increase the amount of circulating free IGF-1, which results in keratinocyte growth and differentiation.

Treatment of AN should focus on correction of the underlying disease process.4 Weight reduction in obesity-related AN may resolve hyperkeratotic lesions, while
correction of hyperinsulinemia can reduce the burden of AN lesions. Cessation of the causative agent in drug-induced AN often results in resolution of AN, and surgical removal of tumors is the mainstay of treatment in malignancy-associated AN. While the goal of therapy for AN is to treat the primary cause, cosmetic resolution of AN lesions can be important for patients and their quality of life. Treatment options have not been extensively studied; however, smaller powered clinical trials and case reports exist in the literature and can aid providers in creating treatment plans for patients with AN. This article aims to explore and evaluate the current treatment options that exist for AN.

A literature search through PubMed was performed using MeSH key words “acanthosis nigricans”, “treatment options”, “metformin”, “isotretinoin”, “acitretin”, “topical therapy”, and “laser”. After reviewing search results for inclusion, a total of 19 articles were retrieved using these keywords in combinations on PubMed. Further articles were found using source materials from the references reviewed and chosen for inclusion. Articles and case reports that focused specifically on AN and its treatment were given preference. Studies and articles published from 1951 to 2017 were used in order to encompass the breadth of the research that has been conducted on the subject. Clinical trial evidence for five recent trials was found using the phrases “acanthosis nigricans” and “treatment” on Clinicaltrials.gov. Review articles and the authors’ experiences were drawn upon to create the discussion section.

**Topical treatments**

**Topical retinoids**

Topical retinoids are considered one of the first-line treatment options for AN. In a study of 30 patients, clinical improvement of treatment-resistant AN was seen in all patients after 14 days of 0.05% tretinoin application (Table 1). Of the 30 patients, 24 (80%) showed total clearance at 16 weeks. However, intermittent tretinoin was needed to maintain improvement as relapse was noted within a period of 4 weeks after discontinuation of treatment. Histopathologically, the typical changes of hyperkeratosis and keratotic material between papillae were resolved on biopsy after 8 weeks of tretinoin application. Use of topical 0.1% tretinoin also improved AN as shown in two case reports. An 18-year-old woman with AN experienced clearance of her neck AN in 10 days, followed by improvement in color and hyperkeratosis of her axillae within 2 weeks. Another patient experienced clearing of left axilla AN after tretinoin 0.1% gel was applied twice daily for 2 weeks, while the right axilla was used as a control and did not show any improvement.

<table>
<thead>
<tr>
<th>Therapy</th>
<th>N</th>
<th>Subject description</th>
<th>Intervention</th>
<th>Primary outcome measure</th>
<th>Study design</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tretinoin 0.1% cream</td>
<td>1</td>
<td>18 yo female with AN</td>
<td>Applied BID to neck and axillae</td>
<td>Clearane of neck in 10 days, improvement of hyperkeratosis and color of axillae within 14 days</td>
<td>Case report</td>
<td>Berger and Gross et al.</td>
</tr>
<tr>
<td>Tretinoin 0.1% gel</td>
<td>1</td>
<td>55 yo Indian male with AN onset 16 weeks after initiating nicotinic acid for dyslipidemia</td>
<td>Applied BID to left axilla</td>
<td>Complete resolution after 2 weeks</td>
<td>Case report</td>
<td>Darmstadt et al.</td>
</tr>
<tr>
<td>Tretinoin 0.05% + hydroxyquinone 4% + fluocinolone acetonide 0.01%</td>
<td>1</td>
<td>39 yo Hispanic female with AN that developed during pregnancy</td>
<td>Applied nightly to neck</td>
<td>Significant improvement after 1 month</td>
<td>Case report</td>
<td>Adigun and Pandya et al.</td>
</tr>
<tr>
<td>Adapalene gel</td>
<td>16</td>
<td>Pediatric patients (mean age 13.4 years) with AN who were at least over 85th BMI percentile for age</td>
<td>Daily application of 0.01% adapalene gel to target side of neck, placebo gel to opposite side of neck, placebo gel to opposite side of neck, placebo gel to opposite side of neck,</td>
<td>Significant improvement in therapeutic side of face, color ratio at 2 and 4 weeks, improved IGE and PGE, and minimal cutaneous irritation</td>
<td>Split, comparison study</td>
<td>Schwartz et al.</td>
</tr>
</tbody>
</table>
### Treatment options for acanthosis nigricans

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Description</th>
<th>Study Type</th>
<th>Participants</th>
<th>Details</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcipotriol 0.005%</td>
<td>Gregoriou et al.</td>
<td>Case report</td>
<td>1 77 yo male with several month history of AN</td>
<td>Applied BID to nape, axilla, umbilicus, groin. Weekley for 1 month, TCA 15% was applied to affected areas (neck, groin, axilla, cheek).</td>
<td>Subjective clinical improvement with complete remission at 4 weeks with no relapse 6 months after stopping treatment.</td>
</tr>
<tr>
<td>Trichloroacetic acid (TCA) peel</td>
<td>Zayed et al.</td>
<td>Pilot study</td>
<td>6 Egyptian females (mean age 31.5 years) who were Fitzpatrick type IV with AN</td>
<td>TCA 15% was applied to affected areas (neck, groin, axilla, cheek).</td>
<td>Subjective clinical improvement with complete remission at 4 weeks with no relapse 6 months after stopping treatment.</td>
</tr>
<tr>
<td>Fish oil</td>
<td>Sherertz</td>
<td>Case report</td>
<td>1 18 yo female with lipodystrophic DM and AN of neck, axilla, and other body folds</td>
<td>Fish oil 10–20 g/day for 6 months.</td>
<td>Subjective clinical improvement with improved AN that persisted 6 months after stopping treatment.</td>
</tr>
<tr>
<td>Acipimox</td>
<td>Coates et al.</td>
<td>Case report</td>
<td>1 40 yo obese female with type V hyperlipidemia and nicotinic acid-induced AN on antecubital fossae and axilla</td>
<td>Substitution of acipimox 250 mg TID</td>
<td>Subjective clinical improvement with complete resolution of AN within weeks with no deterioration of lipid profile.</td>
</tr>
<tr>
<td>Isotretinoin</td>
<td>Katz</td>
<td>Case report</td>
<td>1 33 yo obese female with DM type II and AN of axillae, groin, antecubital fossae, dorsa of hands, angles of mouth, inframammary folds</td>
<td>0.5 mg/kg/day for 1 week, increasing by 0.5 mg/kg/day weekly for 16 weeks. Due to side effects, maintenance dose was 2 mg/kg/day.</td>
<td>Subjective clinical improvement with complete resolution at day 45 with mild recurrence that resolved with topical 0.1% retinoic acid applied daily.</td>
</tr>
<tr>
<td>Acitretin 0.8mg/kg</td>
<td>Ozdemir et al.</td>
<td>Case report</td>
<td>1 18 yo male with no significant medical history with AN across upper abdomen, lateral chest, proximal UE and entire LE</td>
<td>0.8 mg/kg/day for 45 days with 0.4 mg/kg/day maintenance dose.</td>
<td>Subjective clinical improvement with improved AN that persisted 6 months after stopping treatment.</td>
</tr>
<tr>
<td>Metformin</td>
<td>Bellot-Rojas et al.</td>
<td>Randomized, open-label trial</td>
<td>7 Obese or overweight patients with AN of neck</td>
<td>Metformin (n=4) or rosiglitazone (n=3) for 12 weeks.</td>
<td>Subjective clinical improvement with no effect on the severity of AN; modest improvements of skin texture in both groups.</td>
</tr>
<tr>
<td>Octreotide</td>
<td>Romo and Benavides</td>
<td>Case report</td>
<td>1 15 yo obese male with AN of neck and axilla</td>
<td>Octreotide 50 µg subq TID for 5.5 months.</td>
<td>Subjective clinical improvement with improved AN that persisted 6 months after stopping treatment.</td>
</tr>
<tr>
<td>Fish oil</td>
<td>Sherertz</td>
<td>Case report</td>
<td>1 18 yo female with lipodystrophic DM and AN of neck, axilla, and other body folds</td>
<td>Fish oil 10–20 g/day for 6 months.</td>
<td>Subjective clinical improvement with improved AN that persisted 6 months after stopping treatment.</td>
</tr>
<tr>
<td>Acipimox</td>
<td>Coates et al.</td>
<td>Case report</td>
<td>1 40 yo obese female with type V hyperlipidemia and nicotinic acid-induced AN on antecubital fossae and axilla</td>
<td>Substitution of acipimox 250 mg TID</td>
<td>Subjective clinical improvement with complete resolution of AN within weeks with no deterioration of lipid profile.</td>
</tr>
<tr>
<td>Alexandrite laser</td>
<td>Rosenbach and Ram</td>
<td>Case report</td>
<td>1 38 yo Asian-American female with 10-year history of AN of axillae</td>
<td>Long-pulsed (5 m/sec) alexandrite laser at 16–23 J/cm² with spot sizes of 10 mm or 12.5 mm for 10 treatments at 4- to 8-week intervals.</td>
<td>Subjective clinical improvement with greater than 95% improvement after seven treatments in texture and hyperpigmentation with no recurrence at 2-year follow-up. Side effects included moderate discomfort and shallow ulcerations.</td>
</tr>
<tr>
<td>Surgical removal of malignancy</td>
<td>Ghosh et al.</td>
<td>Case report</td>
<td>1 35 yo obese male with AN of neck and insulinoma</td>
<td>Surgical enucleation of the mass</td>
<td>Subjective clinical improvement with at 8 weeks postoperatively, AN had resolved and insulin levels normalized.</td>
</tr>
</tbody>
</table>

**Note:** Studies included are those for which full articles were accessible.

**Abbreviations:** AN, acanthosis nigricans; yo, year old; BID, twice daily; OCP, oral contraceptive pill; DM, diabetes mellitus; UE, upper extremity; LE, lower extremity; subq, subcutaneously; TID, three times daily.
Two studies that used adapalene gel for childhood AN showed variable results.9,10 One randomized controlled trial had 16 children in Thailand use 0.1% adapalene to one side of their neck affected by AN with a minimization of skin darkening found to result. The therapeutic effect was attributed to an alteration in epidermal keratinization, and little to no skin irritation occurred.9 Another split site comparison study of 16 pediatric AN patients treated with 0.1% adapalene gel in India showed 60.7%±28.5% improvement in the mean skin color ratio, defined as ([Felix von Luschan skin color at neck – interscapular skin color]/interscapular skin color). The therapeutic side showed significant improvement as measured by a significant decrease in the mean skin color ratio compared to the untreated side at weeks 2 and 4, respectively.10

Combination therapy may also be used to successfully treat AN. In one case report, the combination of 0.05% tretinoin cream and 12% ammonium lactate cream led to resolution of obesity-related AN.11 In another case report of idiopathic AN, a triple-combination depigmenting cream composed of 0.05% tretinoin, 4% hydroquinone, and 0.01% fluocinolone acetonide was applied at night along with daily sunscreen, which showed successful results after 1 month of use.12

Topical vitamin D analogs
Calcipotriene, a vitamin D analog, is another topical treatment option for AN. It is thought to inhibit keratinocyte proliferation and promote differentiation by increasing keratinocyte intracellular calcium and cyclic GMP levels.3 By reducing the number of keratinocytes, it may minimize the cutaneous effects of insulin.13 One report in the literature demonstrated improvement of a mixed-type AN in the flexural areas of an obese man after 3 months of 0.005% calcipotriol cream application twice daily.14 Another report showed that an obese woman with AN showed improvement in her lesions with calcipotriol ointment use twice daily, which was also for a period of 3 months.15 Gregoriou et al reported calcipotriol to be a safe, effective, and well-tolerated treatment for AN, particularly when etiological treatment is not an option.3,16

Chemical peels
Although considered cosmetic in nature, superficial chemical peels are a relatively safe and effective treatment option for AN. Trichloroacetic acid (TCA) is a chemical exfoliating agent that causes destruction of the epidermis with subsequent repair and rejuvenation.5 As a caustic substance, TCA causes coagulation and precipitation of skin proteins, leading to necrosis of epidermis. This destruction is followed by inflammation and the activation of wound repair, causing re-epithelialization with smoother skin.9 Zayed et al reported improvement in AN in six female patients who used TCA peels in a pilot study. Improvement was seen with regards to hyperpigmentation, thickening, and overall appearance.17 TCA has several advantages: it is safe, easily accessible, inexpensive, and can be easily prepared. Furthermore, TCA is also a stable compound with a known precipitation, absorption, and peel depth, which make judging its endpoint exfoliation simple.3

Oral treatment
Oral retinoids (isotretinoin and acitretin)
Oral retinoids such as isotretinoin and acitretin can also be effective treatment options for AN. However, improvement requires large doses and extended courses, with relapses described in the literature.1,3,18 One proposed mechanism of action for these drugs is normalization of epithelial growth and differentiation.3,19 Extensive AN associated with obesity has been successfully treated with isotretinoin (3 mg/kg/day), but relapsed when treatment was discontinued.20 Another patient noted 90% improvement of palmar AN and 50% improvement of axillary AN within 2 months of taking isotretinoin 80 mg/day. After gradually tapering this dose over more than a year and receiving over a total of 30 g, the patient experienced recurrence of his skin lesions that improved on taking 1000 mg metformin twice daily.21 Another case report of a 17-year-old female with Costello syndrome showed improvement in AN of the neck and dorsum of the hands as a result of oral isotretinoin treatment started for nodulocystic acne.22

Fewer reports of AN treatment with acitretin are present in the literature; however, those that exist report success in cases of syndromic and benign AN.3 One case showed that an 18-year-old male with generalized idiopathic AN experienced complete recovery after 45 days of acitretin 0.8 mg/kg (50 mg) divided into two daily doses. After starting maintenance therapy of 25 mg acitretin daily for 2 months, lesions recurred that subsequently resolved with topical application of 0.1% retinoic acid.23 Because of acitretin’s longer terminal elimination half-life and fewer lipophilic properties, its use may be limited, causing potential for early recurrence.3,24 One case report has also been published on the successful treatment of AN with oral etretinate, a second-generation systemic retinoid in a patient with generalized lipodystrophy.

Metformin and rosiglitazone
For the treatment of AN associated with insulin resistance, conventional insulin-sensitizing agents such as metformin can be used. Metformin increases peripheral insulin responsiveness, resulting in reduction of glucose production,
hyperinsulinemia, body weight, and fat mass, as well as an increase in insulin sensitivity in patients with insulin resistance and AN. One recent clinical trial conducted in India treated 40 patients with AN and insulin resistance (detected by the Homeostatic Model Assessment for Insulin Resistance) with 500 mg metformin thrice daily for 3 months. Compared with 20 control patients who were given placebo, patients treated with metformin demonstrated statistically and clinically significant improvement in AN of the neck and axilla, but not in AN of the knuckles, fingers, or elbows. In one published case series, three obese adolescent patients were started on metformin and dietary modifications. All the patients had previously failed topical therapy for AN, either with calcipotriol or with corticosteroids. Improvement was subjectively seen in all the three patients with no relapse reported after 1 year. Another case report of a 14-year-old boy treated with 850 mg metformin twice daily reported no resolution of AN after 6 months of treatment.

A prospective, randomized, open-label trial compared metformin and rosiglitazone in 27 insulin-resistant patients for 12 weeks. While a greater reduction in fasting insulin levels was seen with rosiglitazone, only minimal improvement in AN lesions and skin texture was seen with either agent. Duration of treatment may also play a role in observing clinical changes to the skin, as metformin does improve both AN and insulin resistance when used for 6 or more months. In a smaller prospective 6-month trial of metformin in patients with AN and insulin resistance, improvement in AN resulted in three of five patients (two adolescents and one adult).

Other oral agents
A combination of metformin with thiazolidiones, medications that increase insulin sensitivity in peripheral muscles, has also been reported to have good results in patients with AN. Hyperandrogenemia, insulin resistance, and AN syndrome (HAIR-AN syndrome) patients may also be treated with a combination of metformin and oral contraceptives. The spontaneous regression of AN has also been reported after the addition of TZD pioglitazone and sitagliptin, a dipeptidyl peptidase 4 inhibitor which increases insulin secretion, in an insulin-resistant patient. The long-term use of ocreotide, a synthetic analog of somatostatin, sustained improvement of AN and reduction of body weight in a severely obese boy with insulin resistance 6 months after treatment cessation.

Other therapies
Other therapies that have improved AN according to published case reports include fish oil, podophyllin, and combination therapy with urea, salicylic acid, and triple combination depigmenting cream. Fish oil containing omega-3 fatty acids improved hyperpigmentation and skin texture in one woman with AN and a lipodystrophic form of diabetes after 6 months of treatment in spite of continued therapy with niacin. Podophyllin 20% in alcohol has been reported to temporarily resolve AN lesions of the hands; however, resolution was preceded by a local reaction after application of the solution. Other treatment options that have been reported with variable results include topical urea and salicylic acid application.

Use of alexandrite laser is another cosmetic treatment option that has been demonstrated to be effective in improving AN lesions. Greater than 95% clearance in the left axilla was observed after seven treatments with long-pulsed (5 msec) alexandrite laser at 4–8 weeks interval. This laser was designed to target melanin in hair and was hypothesized to improve the darkening of the skin in affected areas. Although it is not cost-effective compared to other topical and oral treatment options, the use of alexandrite laser for treatment of AN is promising for the future.

Discussion
Current treatment paradigms for AN are shifting to include addressing the cutaneous pathology as well as the underlying disease or drug. Non-medication options include weight loss and exercise to increase insulin sensitivity in insulin-resistant AN. Treatment of AN is multifactorial because the skin findings are often accompanied by underlying disease. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. Providers should obtain a fasting lipid panel, glucose, and insulin, as well as a complete blood count and liver function testing. If malignancy-associated AN is considered, imaging studies such as plain radiography and computerized tomography/magnetic resonance imaging may provide valuable information. Oral metformin and combinations of other insulin-mediating medications are effective, as they are therapies aimed at resolving the underlying causes contributing to AN.

For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intensive burden.
Other options include dermabrasion or alexandrite laser; however, cost must be considered with these treatments as well the potential for post-inflammatory hyperpigmentation. An important consideration when evaluating a patient with AN is the potential for psychological distress. In one study, obese female adolescents with AN showed significantly lower self-esteem status than the healthy control. Testosterone levels significantly correlated with poor self-esteem scores among the obese females with AN. While correction of underlying causes remains the mainstay of treatment, it is important to consider cosmetic options to improve patient quality of life that may be affected by the presence of AN lesions.

Future studies of AN are currently being conducted, with several trials registered on ClinicalTrials.gov. These include a study of metformin on the treatment of AN in children (NCT02438020), an examination of glucose intolerance in lean children with a family history of diabetes and obese children with AN (NCT00000112), a spectroscopic and colorimetric analysis of AN in hyperinsulinemia patients (NCT01125150), a study of leuprolide acetate and spironolactone on insulin resistant women with hyperandrogenism insulin resistance AN syndrome (NCT00004311), and a study of the effect of the dietary supplement melatonin on obese patients with AN (NCT02604095). While these studies have the potential to shed light on therapy for AN, clinical trials are needed to examine topical and oral treatment options specifically for the improvement of AN skin lesions. The current literature that exists is limited, and higher powered studies with larger patient populations are needed to further elucidate the AN treatment paradigm.

Conclusion

We identified various treatment options for AN including topical, oral and chemical peels. While cosmetic concerns are important aspects of AN treatment, providers must attempt to discover and address any underlying pathology such as diabetes mellitus and cancer. Currently no single treatment of AN is superior; however, as the pathogenesis of AN is further elucidated, more targeted therapies of superficial lesions and associated pathology will greatly benefit these patients.

This review is intended to provide medical professionals with broad treatment options for patients with AN as well as considerations for etiology of the condition. Although the search strategy was designed to capture all peer-reviewed literature of AN treatment, there is the possibility for missing articles. Improved patient understanding of AN and its etiology should be a mainstay of management. Although cosmetic outcomes are an important component of AN, recognition and treatment of the underlying pathology is paramount. Future research in the pathogenesis of insulin-resistant AN and malignancy-related AN will further the development of targeted AN therapies. With more information on therapies that treat the underlying causes of AN, as well as treatment options for the cosmetic appearance of AN lesions, providers will have the opportunity to treat patients underlying diseases and the psychological consequences of the AN to improve patient quality of life.

Disclosure

Dr Feldman is a speaker for Janssen and Taro. He is a consultant and speaker for Galderma, Stiefel/GlaxoSmithKline, Abbott Labs, and Leo Pharma Inc. Dr Feldman has received grants from Galderma, Janssen, Abbott Labs, Amgen, Stiefel/GlaxoSmithKline, Celgene, and Anacor. He is a consultant for Amgen, Baxter, Caremark, Gerson Lehrman Group, Guidepoint Global, Hanall Pharmaceutical Co Ltd, Kikaku, Lilly, Merck & Co Inc, Merz Pharmaceuticals, Mylan, Novartis Pharmaceuticals, Pfizer Inc, Quirent, Suncare Research, and Xenopore. He is on an advisory board for Pfizer Inc. Dr Feldman is the founder and holds stock in Causa Research and is majority owner in Medical Quality Enhancement Corporation. He receives royalties from UpToDate and Xlibris. Dr Patel, Dr Roach, Dr Alinia, and Dr Huang report no conflicts of interest in this work.

References